Hygieia
United States
- Livonia, Michigan
- 02/05/2023
- Series B
- $22,000,000
Hygieia’s d-Nav® Insulin Management System includes an AI-powered application and helps people with Type 2 diabetes use insulin in a safe and effective way. It works by guiding users to adjust their insulin doses – based on changing blood glucose patterns -- every few days rather than three or four times annually. Studies show that some 90 percent of people using our d-Nav® service achieve lower A1c within three months. Patients tell us they feel better; experience fewer complications; spend less time at their physician’s office; and can lower their disease management costs. The d-Nav® insulin management system was developed by two University of Michigan researchers and has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan.
- Industry Medical Equipment Manufacturing
- Website https://d-nav.com/
- LinkedIn https://www.linkedin.com/company/hygieia-inc/
Corgi | $108,000,000 | (Jan 9, 2026)
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026)
Vizgen | $48,000,000 | (Jan 9, 2026)
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Carna Health | $8,000,000 | (Jan 9, 2026)
Valinor(US) | $54,000,000 | (Jan 9, 2026)
Alveus Therapeutics Inc | $160,000,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
EpiBiologics | $107,000,000 | (Jan 9, 2026)
SpangleAI | $15,000,000 | (Jan 9, 2026)
Presto Phoenix, Inc. | $10,000,000 | (Jan 9, 2026)